{"disease":{"id":"onychomycosis-due-to-dermatophyte","name":"Onychomycosis due to dermatophyte","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"efinaconazole","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jublia","generic_name":"EFINACONAZOLE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":"Jublia works by inhibiting the fungal enzyme lanosterol 14α-demethylase, which is essential for the production of ergosterol, a critical component of fungal cell membranes."},{"drug_id":"griseofulvin","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Grifulvin V","generic_name":"GRISEOFULVIN","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"Tubulin Inhibiting Agent [EPC]","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-ultramicrosize","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"FULVICIN P/G 330","generic_name":"GRISEOFULVIN, ULTRAMICROSIZE","company_name":"CHARTWELL RX","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-microsize","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"GRISEOFULVIN","generic_name":"GRISEOFULVIN, MICROSIZE","company_name":"COSETTE","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"Tubulin Inhibiting Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-ultramicrocrystalline","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"GRISACTIN ULTRA","generic_name":"GRISEOFULVIN, ULTRAMICROCRYSTALLINE","company_name":"WYETH AYERST","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"miconazole","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monistat","generic_name":"miconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Imidazole antifungal","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciclopirox","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loprox","generic_name":"CICLOPIROX","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 1","drug_class":"ciclopirox","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-microcrystalline","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"GRIFULVIN V","generic_name":"GRISEOFULVIN, MICROCRYSTALLINE","company_name":"JOHNSON AND JOHNSON","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"penlac","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Penlac","company_name":"9305-9954 Quebec Inc","drug_phase":"phase_2","molecular_target":"Deoxyhypusine hydroxylase, Poly [ADP-ribose] polymerase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03280927","title":"Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Dong-A ST Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}